BERNSTEIN, BARRY,伯斯丁 贝瑞,伯斯丁 貝瑞,DUTTA, SANDEEP,杜塔 珊迪普,LIU, WEI,刘巍,劉巍,PODSADECKI, THOMAS J.,波萨迪奇 汤玛士Ｊ,波薩迪奇 湯瑪士Ｊ,CAMPBELL, ANDREW L.,坎贝尔 安德鲁Ｌ,坎貝爾 安德魯Ｌ,MENON, RAJEEV M.,曼诺 瑞吉夫Ｍ,曼諾 瑞吉夫Ｍ,LIN, CHIH WE
申请号：
TW103109528
公开号：
TWI678205B
申请日:
2014.03.14
申请国别(地区):
TW
年份:
2019
代理人:
摘要：
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.本發明之特徵在於用於治療HCV之無干擾素療法。較佳地，該治療係持續較短之治療時間，例如不超過12週。在一個態樣中，該治療包括向感染HCV之個體投與至少兩種直接作用性抗病毒劑及利巴韋林(ribavirin)，其中該治療持續12週且不包括干擾素之投與，且該至少兩種直接作用性抗病毒劑包含(a)化合物1或其醫藥上可接受之鹽及(b)化合物2或其醫藥上可接受之鹽。
